Halozyme Therapeutics SG&A Expenses 2010-2024 | HALO
- Halozyme Therapeutics annual sg&a expenses for 2023 were $0.149B, a 3.94% increase from 2022.
- Halozyme Therapeutics annual sg&a expenses for 2022 were $0.144B, a 185.21% increase from 2021.
- Halozyme Therapeutics annual sg&a expenses for 2021 were $0.05B, a 10.03% increase from 2020.